icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
YqwBjCZg5pnAQxTE